According to a new report from Product Layers, two new types of research have come forward which could prove to be crucial in the upcoming litigation against Xarelto. Currently facing the heat from more than 2800 lawsuits in a multidistrict litigation, Bayer and Johnson & Johnson – the manufacturers of Xarelto (rivaroxaban), would be cursing their luck after a single glance at the new pieces of evidence.
Contrary to all the other researches – which have either been presented by the plaintiffs or defendants in the court, this research has been carried out by an independent group of researchers. The research generates a well-defined connection between the use of the Novel Oral Anticoagulant (NOAC) and the diseases i.e. gastrointestinal bleeding and eye infection.
The United States Judicial Council has consolidated more than 2200-cases in a single lawsuit. In all these cases common allegations have been filed against Xarelto. The Lawsuit of MDL # 2592 will be presented before Judge Eldon Fallon in the Eastern District of Louisiana.
In addition to this lawsuit, yet another one has been filed in the Philadelphia Court of Common Pleas. In this lawsuit, more than 550 cases have been consolidated to create a mass tort program.
What is Xarelto?
Not a traditional blood thinning medicine by any means, Xarelto revolutionized the drug market after its introduction a few years back. Before its introduction, the likes of warfarin were dominating the drug market. However, once Xarelto was introduced, it became the Number 1 blood thinning drug in the United States.
The major reason for the success of Xarelto was its general dosage for all the patients. Unlike to those of its competitors, a general dose of Xarelto was prescribed by the doctors to all patients. However, in the case of warfarin, blood tests were necessary before dishing out the medicine to the patients.
Research # 1: Linking Xarelto to Vitreous Hemorrhages
The first research, which was carried out by a team of doctors was published in the JAMA Opthalmology’s issue of June 2015. This research took into account the patients who were taking Xarelto from some time. However, in contrast to the other researches, this research was carried out on patients who weren’t parties in the case. Therefore, when it comes to the impartiality of this research, it is safe to say that it would carry huge weight in front of the court.
The patients who were tested in this research aged from 70 – 80. All these patients had used traditional anticoagulants at some stage in their life. Moreover, they had switched to using Xarelto only in the last few years.
As stated by the research in a damning indictment of Xarelto, in “all the cases”, an acute vitreous hemorrhage was formed in the patient after taking Xarelto for some time. Moreover, the doctors voiced their opinion that their research – which would be presented in the court, should refrain the doctors from prescribing the medicine to their patients.
Research # 2: Linking Xarelto to Gastrointestinal Bleeding
In yet another research which was published in the 2015’s April Issue of the British Medical Journal, more damning information was produced linking Xarelto to stomach bleeding. This research will, therefore, present more convincing information to the court.
Under this research, more than 46,000 patients were being tested to carve out the results of taking one of the new blood thinners. As you might note from the scale of information, the result of this research would carry more weight in the court.
Two types of patients were researched in this case. In the first category, those patients were tested who are taking the traditional anticoagulants. In the 2nd one, patients who are on Xarelto were tested.
The researchers noted that in patients who were taking rivaroxaban in place of the traditional blood thinning anti-coagulants, the apparent risk of contracting stomach bleeding was two times greater than their counterparts.
In addition to the above-mentioned researches, one thing that would add to the headache of the the drug’s manufacturers is the ever increasing number of lawsuits. At this stage, they are facing lawsuits in the region of 2800. However, as per the plaintiffs, more and more people will join their forces once an undeniable evidence is presented to the court.
What could be the financial Implications?
In 2013 alone, Bayer and Johnson and Johnson had made more than $1.3billion from the profits of their drugs. Therefore, while the current fiscal numbers are not released by them, it seems that they would have to pay a handsome amount in case of a verdict in favor of the plaintiffs.